CJC-1295 History and Development

Native GHRH and the Problem of Rapid Degradation

Growth hormone-releasing hormone is a 44-amino-acid hypothalamic peptide first isolated and characterized in 1982 by two independent groups led by Guillemin and Vale [1]. The biologically active fragment resides in the first 29 residues (GRF 1-29), which retains full receptor binding and GH-releasing potency [2]. The clinical limitation is speed of destruction. Native GHRH has a plasma half-life of only 5 to 7 minutes because dipeptidyl peptidase IV (DPP-IV) cleaves the Tyr1-Ala2 bond almost immediately after injection [3].

This rapid inactivation made unmodified GHRH impractical for therapeutic use outside of diagnostic testing. Early clinical trials in GH-deficient children using native GHRH(1-29) required twice-daily subcutaneous injections and still produced inconsistent GH peaks [4]. The pharmacokinetic barrier was clear: any clinically viable GHRH analog would need resistance to DPP-IV and longer circulating persistence.

Multiple research groups through the 1990s attempted amino acid substitutions to slow enzymatic cleavage. Sermorelin (GRF 1-29 NH2), approved by the FDA in 1997 under the brand name Geref, represented the first commercial GHRH analog but retained a half-life of only 11 to 12 minutes [5]. It required daily injection and was voluntarily withdrawn from market in 2008 due to supply issues, not safety concerns.

The Four Substitutions: Engineering Modified GRF 1-29

The peptide that became CJC-1295 emerged from systematic structure-activity studies at ConjuChem Biotechnologies in Montreal during 2000-2004. Researchers introduced four amino acid replacements into the GRF(1-29) backbone [6]:

Position 2: Ala → D-Ala (blocks DPP-IV cleavage at the vulnerable N-terminal bond). Position 8: Asn → Gln (prevents asparagine deamidation, a common degradation pathway). Position 15: Gly → Ala (increases alpha-helical stability). Position 27: Met → Leu (eliminates methionine oxidation).

These substitutions collectively increased enzymatic resistance by approximately 700% compared to native GRF 1-29 without compromising receptor binding affinity [6]. The modified peptide retained full agonist activity at the GHRH receptor (GHRH-R), a G-protein coupled receptor expressed on anterior pituitary somatotrophs [7]. This base molecule is what clinicians now call "mod GRF 1-29" or "CJC-1295 without DAC."

The distinction matters clinically. Without the DAC component, modified GRF 1-29 has a half-life of approximately 30 minutes. Longer than sermorelin, but still requiring daily or twice-daily dosing.

Drug Affinity Complex: The Albumin-Binding Innovation

ConjuChem's defining contribution was not merely the amino acid substitutions but the bioconjugation platform they called Drug Affinity Complex (DAC). This technology attached a reactive maleimidopropionic acid (MPA) linker to lysine residue at the C-terminus of the modified GRF 1-29 chain [8].

Once injected subcutaneously, the MPA group forms an irreversible covalent thioether bond with Cys34 of circulating serum albumin [8]. Because albumin has a plasma half-life of 19 to 21 days and is largely excluded from renal filtration, the covalently bound peptide inherits dramatic pharmacokinetic extension [9].

The result: CJC-1295 with DAC achieves a terminal half-life of approximately 5.8 to 8.1 days in humans [10]. This represents a roughly 1,000-fold extension over native GHRH and a 280-fold extension over sermorelin. A single 30 mcg/kg subcutaneous injection can maintain elevated GH pulsatility for more than one week.

ConjuChem filed patent applications for the DAC platform beginning in 2001 (US Patent 6,849,714), covering the bioconjugation chemistry broadly applicable to multiple peptide therapeutics [8]. The company also explored DAC-linked GLP-1 analogs and other short-lived peptides, though CJC-1295 advanced furthest in clinical development.

Mechanism of Action: Pulsatile GH Release Through GHRH-R Agonism

CJC-1295 stimulates growth hormone secretion through a defined receptor-mediated pathway. The peptide binds the GHRH receptor on somatotroph cells in the anterior pituitary, activating adenylyl cyclase via Gs-alpha protein coupling [7]. This increases intracellular cyclic AMP, which activates protein kinase A and ultimately promotes GH gene transcription, GH synthesis, and exocytotic GH release [11].

A defining characteristic: CJC-1295 preserves pulsatile GH secretion patterns rather than producing a continuous, non-physiologic GH elevation [10]. The Teichman 2006 trial demonstrated that mean GH concentrations increased 2 to 10-fold after CJC-1295 DAC injection, but GH continued to be released in discrete pulses rather than a flat plateau [10]. This is a pharmacodynamic advantage over exogenous recombinant GH, which produces supraphysiologic peaks followed by rapid troughs.

The negative feedback axis remains intact. Somatostatin tone still modulates GH pulse amplitude and frequency, and IGF-1 feedback at the hypothalamic level continues to operate [12]. This preserved feedback explains why CJC-1295 does not typically produce GH levels exceeding acromegalic thresholds in clinical dosing studies.

Downstream, the GH elevation stimulates hepatic IGF-1 production. In the Teichman trial, IGF-1 levels rose 1.5 to 3-fold above baseline and remained elevated for 6 to 14 days after a single injection [10]. Standard deviation of IGF-1 was dose-dependent, increasing most notably at the 60 and 90 mcg/kg dose levels.

Key Clinical Trials and Pharmacokinetic Data

The most cited human dataset comes from Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006 [10]. This was a dose-escalation study in healthy adults aged 21 to 61 examining single and multiple subcutaneous doses of CJC-1295 DAC at 30, 60, and 90 mcg/kg.

Primary findings: GH concentrations increased 2 to 10-fold for 6 days or longer after injection. IGF-1 concentrations increased 1.5 to 3-fold for 9 to 11 days. No serious adverse events were reported. Injection-site reactions were the most common side effect, occurring in 6 of 33 subjects [10].

After multiple weekly doses, IGF-1 levels showed dose-proportional accumulation with mean elevations reaching 2.5 to 3.0-fold by the second or third dose [10]. GH pulsatility was preserved across all dose cohorts.

Earlier preclinical work by Jette et al. (2005) characterized the pharmacokinetics in rats and demonstrated that DAC bioconjugation increased the area under the curve (AUC) for GH stimulation by more than 10-fold versus unconjugated modified GRF 1-29 [13]. The same group showed that the albumin-binding reaction reached completion within 15 minutes of subcutaneous injection in vivo.

A separate study by Alba et al. (2006) in the same journal examined CJC-1295 DAC over multiple weekly doses and confirmed sustained IGF-1 elevation without tachyphylaxis over the 4-week study period [14]. GH response to each subsequent dose remained consistent, suggesting no receptor desensitization with weekly administration.

ConjuChem's Clinical Program and Its Discontinuation

ConjuChem Biotechnologies advanced CJC-1295 through Phase I and early Phase II trials between 2004 and 2006 for indications including adult GH deficiency, HIV-associated lipodystrophy, and age-related sarcopenia. The company initiated a Phase II trial in HIV-associated visceral adiposity (ClinicalTrials.gov NCT00235469) [15].

The clinical program stalled after 2006 for financial rather than safety reasons. ConjuChem encountered funding difficulties and eventually filed for creditor protection under Canadian insolvency law in 2007. The company's assets, including the DAC platform patents, were subsequently acquired. No Phase III trials for CJC-1295 were ever completed.

This financial termination is significant context for regulatory discussions. CJC-1295 did not fail a safety trial. The compound was never rejected by the FDA on efficacy or toxicity grounds. It simply never completed the registration pathway.

Distinction: CJC-1295 With DAC vs. Without DAC (Mod GRF 1-29)

Clinical and compounding contexts now use "CJC-1295" to refer to two distinct molecules, and conflation between them causes prescribing confusion [16].

CJC-1295 with DAC: the original ConjuChem compound, half-life of 5.8 days, dosed once weekly, produces sustained multi-day GH elevation. CJC-1295 without DAC (mod GRF 1-29): the same four-substitution peptide backbone but lacking the MPA-albumin linker, half-life of approximately 30 minutes, requires daily or multiple-daily dosing, produces acute GH pulses lasting 2 to 3 hours.

In current compounding pharmacy practice, the non-DAC form is far more commonly dispensed [16]. Many practitioners pair it with a ghrelin-mimetic peptide such as ipamorelin to amplify the GH pulse through dual-receptor activation at the pituitary level [17]. The combination activates both GHRH-R and GHS-R1a simultaneously.

Current Regulatory and Compounding Status

CJC-1295 (both variants) has never received FDA approval for any indication. It is not listed in the FDA Orange Book. The peptide is currently available in the United States through 503A compounding pharmacies that produce it pursuant to valid patient-specific prescriptions [16].

The FDA's November 2023 update to its draft guidance on bulk drug substances under 503A and 503B nominated several peptides for potential removal from compounding eligibility [18]. As of May 2026, CJC-1295 remains available through licensed compounding pharmacies, though its regulatory future is subject to ongoing FDA evaluation of peptide compounding categories.

The Endocrine Society has not issued formal clinical practice guidelines for CJC-1295 due to the absence of Phase III data [19]. Prescribing occurs on an off-label, clinician-directed basis, typically for patients presenting with documented GH insufficiency, age-related decline in GH pulsatility, or body composition goals in the context of medically supervised optimization protocols.

Safety Profile From Available Human Data

Across published human trials, CJC-1295 DAC demonstrated a generally mild adverse event profile [10][14]. The most frequently reported effects were injection-site erythema and induration (18% of subjects), transient flushing (9%), and headache (6%). No subjects withdrew due to adverse events in the Teichman or Alba studies.

Water retention and paresthesias, common with exogenous GH administration, were not reported at the studied doses. This may reflect the fact that CJC-1295 produces physiologic-range GH elevation rather than the supraphysiologic peaks seen with injectable somatropin [20].

Long-term safety data beyond 12 weeks of dosing do not exist in published literature. Theoretical risks associated with prolonged GH axis stimulation include accelerated neoplastic growth in patients with occult malignancy, though no cases have been reported in CJC-1295 trials specifically [19]. Standard practice includes baseline cancer screening and periodic IGF-1 monitoring during therapy.

The Broader Context of GH Secretagogue Development

CJC-1295 emerged during a period of intense pharmaceutical interest in GH secretagogues spanning 1995 to 2010. Parallel development tracks included the ghrelin-mimetic class (MK-677, hexarelin, GHRP-6, ipamorelin) operating through a distinct receptor [17]. The academic rationale centered on age-related GH decline (somatopause), documented by Iranmanesh et al. (1991), showing a 14% reduction in GH secretion per decade after age 30 [21].

CJC-1295 DAC represented the most pharmacokinetically advanced GHRH analog to reach human trials. Its albumin-binding approach predated similar strategies later adopted for GLP-1 receptor agonists (semaglutide uses fatty-acid albumin binding, achieving a comparable half-life extension principle) [9]. The parallel is instructive: the same pharmacokinetic problem (rapid peptide degradation) was solved through albumin affinity in both therapeutic classes, but GLP-1 agonists reached FDA approval while CJC-1295 did not, due entirely to the sponsoring company's financial collapse rather than a molecular or safety failure.